drugset / Trial / NCT06511076

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

NCT06511076

Phase 1 Completed 14 enrolled UCB Biopharma SRL
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the bioequivalence pharmacokinetics, safety, tolerability and device deficiencies of zilucoplan (ZLP) in healthy adult participants

Timeline

Start
2024-08-05
Primary completion
2024-11-26
Completion
2024-11-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Zilucoplan Peptide Subcutaneous

Indications

No indication recorded.